Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...
Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...
StockStory.org on MSN
3 reasons PFE is risky and 1 stock to buy instead
Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock ...
Barchart on MSN
Is Pfizer Stock Underperforming the Dow?
Founded 170 years ago and currently headquartered in New York, Pfizer Inc. (PFE) is a global biopharmaceutical powerhouse ...
Zacks Investment Research on MSN
Pfizer (PFE) exceeds market returns: Some facts to consider
Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.68 ...
Fintel reports that on December 15, 2025, B of A Securities maintained coverage of Pfizer (NYSE:PFE) with a Neutral ...
Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...
Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant Pfizer ($PFE) for ...
Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback